Skip to main content

Table 1 Therapeutic goals explored in the analysis

From: Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals

Selected ADA goals

Composite of Selected ADA Goals

HbA1c <7.0%

HbA1c <7.0%, no weight gain, and no hypoglycemia†

*HbA1c ≤6.5%

HbA1c ≤6.5%, no weight gain, and no hypoglycemia†

**FBG <6.99 mmol/L

HbA1c <7.0%, SBP <130 mm Hg, and LDL <2.59 mmol/L

No weight gain

HbA1c ≤6.5%, SBP <130 mm Hg, and LDL <2.59 mmol/L

Any weight loss

 

No hypoglycemia†

 

SBP <130 mm Hg

 

LDL <2.59 mmol/L

 
  1. *Actual ADA goal is <6.5% if it can be achieved without significant hypoglycemia.
  2. **Not an ADA goal (diabetes diagnosis).
  3. †Hypoglycemia is defined as documented blood glucose <3 mmol/L (<54 mg/dL).
  4. Glucose conversion factor, 0.05551; LDL conversion factor, 0.02586.
  5. FBG, fasting blood glucose; LDL, low density lipoprotein cholesterol; SBP, systolic blood pressure.